A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer-Reference-Cited by-同舟云学术

A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer

Published:2006-04 Issue:4 Volume:17 Page:663-667
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Schmittel A.,von Weikersthal L. Fischer,Sebastian M.,Martus P.,Schulze K.,Hortig P.,Reeb M.,Thiel E.,Keilholz U.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/17/4/663/685335/mdj137.pdf

Reference18 articles.

1. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group;Roth;J Clin Oncol,1992

2. A randomized trial of hybrid administration of cyclophosphamide, doxorubicin, and vincristine (CAV)/Cisplatin and etoposide (PVP) versus sequential administration of CAV-PVP for the treatment of patients with small cell lung carcinoma

3. Topotecan versus cyclophosphamide, doxorubicine, and vincristine for the treatment of recurrent small cell lung cancer;Von Pawel;J Clin Oncol,1999

4. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small lung cancer;Noda;N Engl J Med,2002

5. Phase II study of irinotecan and carboplatin in patients with the refractory or relapsed small cell lung cancer;Hirose;Lung Cancer,2003

Cited by 71 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Gegenwärtiger Einsatz und aktuelle Entwicklungen der Immuncheckpointinhibition beim metastasierten und lokalisierten kleinzelligen Lungenkarzinom;Die Onkologie;2024-07-20

2. Comparison of Irinotecan/carboplatin versus Etoposide/carboplatin for extended disease small cell lung cancer (ED-SCLC): A systematic review and meta-analysis of randomized controlled trials;2024-03-07

3. Acquired Cross-Resistance in Small Cell Lung Cancer due to Extrachromosomal DNA Amplification of MYC Paralogs;Cancer Discovery;2024-02-21

4. Acquired Cross-resistance in Small Cell Lung Cancer due to Extrachromosomal DNA Amplification ofMYCparalogs;2023-06-26

5. Efficacy and toxicity profile of first‐line treatment for extensive‐stage small cell lung cancer: A Bayesian network meta‐analysis;Cancer Medicine;2023-03-23